請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73236
標題: | 評估治療性胸腔手術與白細胞介素17相關之肺部疾病 Assessment of a Novel Protocol of Therapeutic Surgery and the Complicated Role of Interleukin-17 in the Pulmonary Diseases |
作者: | Chen-Hao Hsiao 蕭丞皓 |
指導教授: | 周玉山(Yuh-Shan Jou) |
關鍵字: | 肺部疾病,癌抗原19-9, pulmonary disease,CA 19-9, |
出版年 : | 2019 |
學位: | 博士 |
摘要: | Pneumonia may progress to parapneumonic empyema. Streptococcus pneumoniae is the common pathogen. IL-17 produced by Th17 cells has a role to against Streptococcus pneumonia. However, old age and heart failure with reduced left ventricular ejection fraction are high risks for operation. This kind of patients developing parapneumonic empyema remain challenges for surgeons. To overcome this problem, a novel therapeutic protocol using non-intubated video assisted thoracoscopic surgery was applied. We investigated the morbidities, mortality, and quality of life in high risk parapneumonic empyema patients. There were two methods, conventional tube thoracostomy and non-intubated video assisted thoracoscopic surgery, to deal with the patients. The novel therapy surgery was proven to have better results of morbidities, mortality, and quality of life than conventional tube thoracostomy.
IL-17 of Th 17 response not only involves pulmonary inflammation, but promotes non-small cell lung cancer development. Epidermal growth factor receptor tyrosine kinase inhibitor therapy is the main treatment in advanced stage lung cancer patients harbored EGFR mutation. We retrospectively investigated the clinical characteristics and treatment outcomes of advanced stage lung cancer patients treated with tyrosine kinase inhibitor therapy. Non-smokers have a benefit in overall survival. Unfortunately, there are no good biomarkers to predict overall survival in advanced stage lung cancer. We detected sialylated LewisA, a cancer related O-glycan or CA 19-9, on lung cancer tumor cells. Immunohistochemistry staining was performed using sialylated LewisA antibody. There were sixty-six advanced stage patients receiving tyrosine kinase inhibitor therapy in our study. Positive immunohistochemistry staining patients (n=37) had better overall survival than negative immunohistochemistry staining patients (median survival time: 29.9 versus 12.5 months; p = 0.006). In proper selected lung cancer patients, sialylated LewisA or CA 19-9 immunohistochemistry staining may serve as a biomarker to predict overall survival. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73236 |
DOI: | 10.6342/NTU201901127 |
全文授權: | 有償授權 |
顯示於系所單位: | 基因體與系統生物學學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 2.58 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。